Syngene International Limited IPO Review – Subscribe or Not?

by Shiv Kukreja on July 28, 2015

in IPO/NFO

This post is written by Shiv Kukreja, who is a Certified Financial Planner and runs a financial planning firm, Ojas Capital in Delhi/NCR. He can be reached at [email protected]

Pharma sector stocks have been rising on the bourses for the last one year or so. Some stocks have given more than 50% returns in the last 9-12 months. Boosted by a recovery in the US and the European markets, these companies have reported good sales and profit growth. Investors have also given a big thumbs up to these companies resulting in huge gains.

But, the last 10-15 days have been troublesome for these stocks. A few days back, Sun Pharma issued a profit warning resulting in a selloff in its own stocks as well as other pharma stocks as well, followed by a disappointing quarterly performance by Lupin Limited. These two events have shaken the investors’ confidence in the sector.

Just when the sentiment has turned negative for the sector and for the markets as well, , a 83.6% subsidiary of Biocon Limited, has come out with its initial public offer (IPO). The issue consists of an offer for sale by the company’s promoter Biocon Limited. Biocon plans to sell its 11% stake in this IPO selling 2.2 crore shares in the price band of Rs. 240-250, thus raising Rs. 550 crore from the primary markets. The issue got opened yesterday and will get closed tomorrow.

About Syngene Limited

Incorporated in 1993 and headquartered in Bengaluru, India, Syngene is a 83.6% subsidiary of Biocon Limited. The company is one of the leading contract research organisations (CRO), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) across industrial sectors, including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies.

Syngene’s service offerings in discovery and development cover multiple domains across small molecules, large molecules, antibody-drug conjugates (ADC) and oligonucleotides. Its integrated discovery and development platforms help organisations conduct discovery, development and pilot manufacturing under one roof with a distinctive economic advantage. The company intends to forward integrate into commercial-scale manufacturing of NMEs.

The company has several long-term relationships and multi-year contracts with its clients, including three long-duration multi-disciplinary partnerships, each with a dedicated research centre, with three of the world’s leading global healthcare organisations Bristol-Myers Squibb, Abbott Laboratories (Singapore) Pte. Ltd. and Baxter International, Inc.

What’s on Offer?

Syngene has fixed its price band to be between Rs. 240-250 per share. There is no discount for the retail investors. The issue is a complete offer for sale of shares by its promoter, Biocon Limited. Syngene will not receive any proceeds in this offer.

The offer comprises of a sale of approximately 2.2 crore shares to the investors. 35% of the issue size is reserved for the retail individual investors. At Rs. 250 per share, Biocon is expected to raise approximately Rs. 550 crore.

Anchor Investors – Syngene issued approximately 60 lakh shares to the Anchor Investors, namely GIC, Goldman Sachs, Morgan Stanley, Deutsche Bank etc., at Rs. 250 per share, thereby raising Rs. 150 crore.

Bid Lot Size – Investors need to bid for a minimum of 60 shares and in multiples of 60 shares thereafter. So, a retail investor would be required to invest a minimum of Rs. 15,000 at the upper end of the price band and Rs. 14,400 at the lower end of the price band.

Objective of the Issue – There is no fresh issue of equity shares by Syngene in this IPO. The funds raised by the sale of shares in this offer will not go to the company. The primary objectives of the offer are to achieve the benefits of listing and carry out the share sale by the promoter Biocon. Funds mobilized will be utilized for the capex planned by Biocon for developing its biosimilars and enhancing the manufacturing capacities.

Listing – The shares of the company will get listed on both the exchanges i.e. National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).

Financials of the CompanyPicture 3

Note: Figures are in Rs. Crore, except per share data & percentage figures.

For the financial year ended March 31, 2015, Syngene reported total revenue of Rs.  871.6 crore as against Rs. 707.7 crore for the year ended March 31, 2014. The company reported profit after tax (PAT) of Rs. 175 crore for the financial year ended March 31, 2015 as against Rs. 134.8 crore for the financial year ended March 31, 2014.

The company reported EBITDA margin of 33.59% for the period ended December 31, 2015, 31.45% for the year ended March 31, 2014 and 31.16% for the year ended March 31, 2013.

Should You Subscribe or Not?

Syngene has been performing consistently well in an uncertain business environment and contributing significantly to its parent Biocon. The company is seeking a valuation of 28.6 times its FY15 earnings, which seems to me on a slightly higher side. I think for a consistently growing company with strong fundamentals, a strong promoter group, efficient management and a talented team of qualified scientists, these valuations are reasonably justified. I expect its stock price to list at a premium of 20-30% and to double from its expected allotment price of Rs. 250 in the next 2-3 years time.

{ 25 comments… read them below or add one }

santonu July 28, 2015 at 6:20 PM

I have decided to apply for it. Retail portion likely to over scribed by 4-5 times

Reply

Shiv Kukreja July 29, 2015 at 10:58 AM

Seeing a very good demand from the QIBs, Corporates & HNIs. Retail investors also investing in good numbers.

Reply

Shiv Kukreja July 29, 2015 at 4:25 PM

You guessed it very accurately Santonu! 🙂

Reply

santonu July 29, 2015 at 5:30 PM

thanks

Reply

Shiv Kukreja July 29, 2015 at 4:24 PM

Final Day (July 29) Subscription Figures:

Category I – Qualified Institutional Buyers (QIBs) – 51.47 times
Category II – Non Institutional Investors (NIIs) – 90.24 times
Category III – Retail Individual Investors (RIIs) – 4.77 times
Category IV – Shareholders – 1.37 times
Total Subscription – 32.05 times

Reply

Vishal July 29, 2015 at 5:06 PM

I have a trading account but my broker doesn’t allow to apply for IPOs. I also wanted to invest in this IPO. How can I apply? Please let me know.

Thanks.
Regards,

Reply

Shiv Kukreja July 29, 2015 at 5:39 PM

This issue is closed now. You should ask your broker the reason for not allowing you to apply. You can also get another trading account opened which allows you to apply in such IPOs.

Reply

Shiv Kukreja July 30, 2015 at 6:18 AM

Syngene IPO closed on – July 29, 2015
Finalization of Basis of Allotment – On or about August 7, 2015
Initiation of Refunds – On or about August 8, 2015
Credit of Shares to Demat Accounts – On or about August 11, 205
Listing / Commencement of Trading – On or about August 12, 2015

Reply

Shiv Kukreja August 6, 2015 at 6:41 PM

Syngene IPO Update – Retail Investors will be allotted 60 shares in the ratio of 307:825

Reply

Shiv Kukreja August 6, 2015 at 6:43 PM

Syngene IPO Allotment Status Link – http://kosmic.karvy.com:81/ipotrack/

Reply

Vishnu August 6, 2015 at 7:52 PM

Hi Shiv,

I’m a newbie investor, I applied for a single lot and got it 🙂
But, 15k is about 33% of my total portfolio. Should I hold the shares or sell few off? I guess the listing price will be ~15-20% higher as the IPO was subscribed multiple times.

Thanks in advance,
Vishnu

Reply

Shiv Kukreja August 7, 2015 at 7:18 AM

Hi Vishnu,
If I were at your place, I would have booked partial profits in Syngene and diversified my portfolio.

Reply

Manoj August 10, 2015 at 4:42 AM

My suggestion is to liquidate and sit tight till Nifty falls below 8300 (in 3 months it will happen). Then, diversify your portfolio with Axis Bank (20%), SBI (20%), Coal India (30%) and Sun Pharma (30%) and sit tight for 2 years. Don’t even look at your portfolio for those 2 years.

Reply

Subbu August 7, 2015 at 3:28 AM

Hi Shiv, looks like some sort of lottery allotment. I didn’t get any in retail cat.. While my wife got 60..
Regards
Subbu

Reply

Shiv Kukreja August 7, 2015 at 7:37 AM

Yes Subbu, it is a lottery system of allotment. Shares have been allotted in the ratio of 307 applicants for every 825 applicants.

Reply

KK August 7, 2015 at 9:27 AM

Hi
what is the excepted listing price of syngene.

Reply

KM Nair August 10, 2015 at 5:22 AM

May list around 280 -290 (12 to 15% higher than issue price)

Reply

Shiv Kukreja August 10, 2015 at 1:17 PM

Syngene International IPO shares to get listed on the exchanges tomorrow i.e. August 11, 2015. Date of allotment is August 6, 2015. ISIN Code is INE398R01022. NSE/BSE codes for the same are: NSE Code – SYNGENE, BSE Code – 539268

Reply

Shiv Kukreja August 11, 2015 at 10:42 AM

Syngene International got listed on the exchanges today. It listed at Rs. 295 on the NSE, touched a high of Rs. 318.50, a low of Rs. 295 and closed at Rs. 310.55.

Reply

Piyush Agarwal August 19, 2015 at 10:49 AM

Hi

I would like to know your recommendation on three upcoming IPO’

1. Navkar Corportaion
2. Pennar Engineers building
3. Shree Puskar chemical & fertilizer ltd.

Regards
Piyush

Reply

Shiv Kukreja August 21, 2015 at 5:27 PM

Hi Piyush,
I have not analysed any of them as yet. If I get a chance to do that, I’ll post a review here.

Reply

Shiv Kukreja August 21, 2015 at 5:26 PM

Power Mech Projects IPO Allotment Status Link – http://kosmic.karvy.com:81/ipotrack/

Reply

Terry Reitman September 5, 2015 at 2:24 AM

SEBI advises investors to get the allotment in demat form as the shares in IPO are tradable only in demat segment in the stock exchanges.

Reply

Navita March 5, 2016 at 12:47 PM
Navita March 5, 2016 at 12:47 PM

Leave a Comment

Previous post:

Next post: